RESUMEN
Naturally occurring compounds such as sesquiterpenes and sesquiterpenoids (SQTs) have been shown to modulate GABAA receptors (GABAA Rs). In this study, the modulatory potential of 11 SQTs at GABAA Rs was analyzed to characterize their potential neurotropic activity. Transfected HEK293 cells and primary hippocampal neurons were functionally investigated using electrophysiological whole-cell recordings. Significantly different effects of ß-caryophyllene and α-humulene, as well as their respective derivatives ß-caryolanol and humulol, were observed in the HEK293 cell system. In neurons, the concomitant presence of phasic and tonic GABAA R configurations accounts for differences in receptor modulation by SQTs. The in vivo presence of the γ2 and δ subunits is important for SQT modulation. While phasic GABAA receptors in hippocampal neurons exhibited significantly altered GABA-evoked current amplitudes in the presence of humulol and guaiol, negative allosteric potential at recombinantly expressed α1 ß2 γ2 receptors was only verified for humolol. Modeling and docking studies provided support for the binding of SQTs to the neurosteroid-binding site of the GABAA R localized between transmembrane segments 1 and 3 at the (+ α)-(- α) interface. In sum, differences in the modulation of GABAA R isoforms between SQTs were identified. Another finding is that our results provide an indication that nutritional digestion affects the neurotropic potential of natural compounds.
Asunto(s)
Antagonistas de Receptores de GABA-A/farmacología , Simulación del Acoplamiento Molecular/métodos , Extractos Vegetales/farmacología , Receptores de GABA-A/fisiología , Sesquiterpenos/farmacología , Regulación Alostérica/efectos de los fármacos , Regulación Alostérica/fisiología , Animales , Femenino , Antagonistas de Receptores de GABA-A/química , Antagonistas de Receptores de GABA-A/aislamiento & purificación , Células HEK293 , Humanos , Ratones , Neuronas/efectos de los fármacos , Neuronas/fisiología , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Embarazo , Receptores de GABA-A/química , Sesquiterpenos/química , Sesquiterpenos/aislamiento & purificaciónRESUMEN
Development of resistance against existing anti-epileptic drugs has alarmed the scientific innovators to find novel potential chemical starting points for the treatment of epilepsy and GABAA inhibition is a promising drug target strategy against epilepsy. The crystal structure of a subtype-selective ß3-homopentameric ligand-gated ion channel of GABAA receptor has been used for the first time for screening the Asinex library for discovery of GABAA agonists as potential anti-epileptic agents. Co-crystallized ligand established the involvement of part of the ß7-ß8 loop (Glu155 and Tyr157) and ß9-ß10 loop (Phe200 and Tyr205) residues as the crucial amino acids in effective binding, an essential feature, being hydrogen bond or ionic interaction with Glu155 residue. Top ranked hits were further subjected to binding energy estimation, ADMET analysis and ligand efficiency matric calculations as consecutive filters. About 19 compounds qualifying all parameters possessed interaction of one positively charged group with Glu155 with good CNS drug-like properties. Simulation studies were performed on the apo protein, its complex with co-crystallized ligand and the best hit qualifying all screening parameters. The best hit was also analyzed using Quantum mechanical studies, off-target analysis and hit modification. The off-target analysis emphasized that these agents did not have any other predicted side-effects.
Asunto(s)
Epilepsia/tratamiento farmacológico , Agonistas de Receptores de GABA-A/química , Agonistas de Receptores de GABA-A/farmacología , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Teoría Cuántica , Receptores de GABA-A/metabolismo , Benzamidinas/química , Benzamidinas/metabolismo , Benzamidinas/farmacología , Benzamidinas/uso terapéutico , Evaluación Preclínica de Medicamentos , Agonistas de Receptores de GABA-A/metabolismo , Agonistas de Receptores de GABA-A/uso terapéutico , Humanos , Ligandos , Conformación Proteica , Receptores de GABA-A/química , Relación Estructura-Actividad , Interfaz Usuario-ComputadorRESUMEN
Positive modulation of the muscarinic M1-receptor has for a long time attracted scientists and drug developers for the potential treatment of Alzheimer's disease or Schizophrenia. The precognitive potential of M1 activation has however not been clinically demonstrated as a result of side effects associated both with agonists and positive allosteric modulators (PAM's) of the M1-receptor. To avoid excessive activation of the M1-receptor we have designed a new screening format and developed the first low-shift positive allosteric modulators for the M1 receptor. Low-shift PAM's offer the potential of "use-dependent" attenuation of transmitter-signaling while avoiding pseudo-agonistic behavior in vivo as a common limitation of the so far described high-shift PAM's. With these novel M1-PAM's, the M1 receptor is potentially the first GPCR for which both, high- and low shift PAM's have become available.
Asunto(s)
Receptor Muscarínico M1/metabolismo , Regulación Alostérica , Animales , Células CHO , Cricetinae , Cricetulus , Evaluación Preclínica de Medicamentos , Agonistas de Receptores de GABA-A/química , Agonistas de Receptores de GABA-A/metabolismo , Humanos , Agonistas Muscarínicos/química , Mutagénesis Sitio-Dirigida , Receptor Muscarínico M1/química , Receptor Muscarínico M1/genética , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Relación Estructura-ActividadRESUMEN
BACKGROUND: A variety of evidence suggested that an imbalance in excitatory and inhibitory neurotransmission could be one of the pathophysiological mechanisms underlying the occurrence and progression of seizures. Understanding the causes of this imbalance may provide essential insight into the basic mechanisms of epilepsy and may uncover novel targets for future drug therapies. Accordingly, GABA is the most important inhibitory neurotransmitter in the CNS and its receptors (e.g., GABAARs) can still be relevant targets of new antiepileptic drugs (AEDs). METHODS: Up to now, a variety of modulating agents that directly or indirectly act at GABAARs have been proposed for restoring the physiological balance of excitation and inhibition in the epileptogenic brain. While benzodiazepine, barbiturates and allosteric modulators of GABAARs are well-known for their anticonvulsant effect, new compounds as modulators of chloride homeostasis or phytocannabinoids are not completely unraveled and their antiepileptic action is still matter of debate. In addition, several inflammatory mediators as cytokines and chemokines play an important role in the modulation of GABAAR function, even if further research is needed to translate these new findings from the bench to the bedside. Finally yet importantly, a new frontier in epilepsy research is represented by the observation that specific small noncoding RNAs, namely miRNAs, may regulate GABAAR function paving the road to therapeutic approaches based on the modulation of gene expression. CONCLUSION: Here, we review key physiological, neuropathological and functional studies that altogether strengthen the role of modulation of GABAARs function as therapeutic target. The discovery of the novel molecular mechanisms underlying the GABAergic transmission in epilepsy represents another heavy piece in the "epileptic puzzle". Even if GABAAR is an old story in the pharmacology of the epilepsy, the reviewed findings suggest that new players in the scenario need to be considered.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsia/tratamiento farmacológico , Epilepsia/patología , Receptores de GABA-A/química , Animales , Epilepsia/metabolismo , HumanosRESUMEN
Gamma-aminobutyric acid type A (GABAA) receptors are major inhibitory neurotransmitter receptors in the central nervous system and a target for numerous clinically important drugs used to treat anxiety, insomnia, and epilepsy. A series of allosteric GABAA receptor agonists was identified previously with the aid of HPLC-based activity profiling, whereby activity was tracked with an electrophysiological assay in Xenopus laevis oocytes. To accelerate the discovery process, an approach has been established for HPLC-based profiling using a larval zebrafish (Danio rerio) seizure model induced by pentylenetetrazol (PTZ), a pro-convulsant GABAA receptor antagonist. The assay was validated with the aid of representative GABAergic plant compounds and extracts. Various parameters that are relevant for the quality of results obtained, including PTZ concentration, the number of larvae, the incubation time, and the data analysis protocol, were optimized. The assay was then translated into an HPLC profiling protocol, and active compounds were tracked in extracts of Valeriana officinalis and Magnolia officinalis. For selected compounds the effects in the zebrafish larvae model were compared with data from in silico blood-brain barrier (BBB) permeability predictions, to validate the use for discovery of BBB-permeable natural products.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Pentilenotetrazol/farmacología , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Raíces de Plantas/química , Receptores de GABA-A/efectos de los fármacos , Receptores de GABA-A/metabolismo , Convulsiones/tratamiento farmacológico , Valeriana/química , Animales , Estructura Molecular , Pentilenotetrazol/administración & dosificación , Pentilenotetrazol/química , Extractos Vegetales/química , Raíces de Plantas/metabolismo , Receptores de GABA-A/química , Xenopus laevis , Pez CebraRESUMEN
δ-Containing GABAA receptors are located extrasynaptically and mediate tonic inhibition. Their involvement in brain physiology positions them as interesting drug targets. There is thus a continued interest in establishing reliable recombinant expression systems for δ-containing GABAA receptors. Inconveniently, the recombinant expression of especially α4 ß1/3 δ receptors has been found to be notoriously difficult, resulting in mixed receptor populations and/or stoichiometries and differential pharmacology depending on the expression system used. With the aim of developing a facile and robust 96-well format cell-based assay for extrasynaptic α4 ß1/3 δ receptors, we have engineered and validated a HEK293 Flp-In™ cell line stably expressing the human GABAA δ-subunit. Upon co-transfection of α4 and ß1/3 subunits, at optimized ratios, we have established a well-defined system for expressing α4 ß1/3 δ receptors and used the fluorescence-based FLIPR Membrane Potential (FMP) assay to evaluate their pharmacology. Using the known reference compounds GABA and THIP, ternary α4 ß1/3 δ and binary α4 ß1/3 receptors could be distinguished based on potency and kinetic profiles but not efficacy. As expected, DS2 was able to potentiate only δ-containing receptors, whereas Zn2+ had an inhibitory effect only at binary receptors. By contrast, the hitherto reported δ-selective compounds, AA29504 and 3-OH-2'MeO6MF, were non-selective. The expression system was further validated using patch clamp electrophysiology, in which the superagonism of THIP was confirmed. The established FMP assay set-up, based on transient expression of human α4 and ß1/3 subunits into a δ-subunit stable HEK293 Flp-In™ cell line, portrays a simple 96-well format assay as a useful supplement to electrophysiological recordings on δ-containing GABAA receptors.
Asunto(s)
Proteínas del Tejido Nervioso/metabolismo , Receptores de GABA-A/metabolismo , Colorantes Fluorescentes/química , Agonistas del GABA/farmacología , Células HEK293 , Humanos , Inmunohistoquímica , Cinética , Potenciales de la Membrana/efectos de los fármacos , Microscopía Confocal , Mutación , Proteínas del Tejido Nervioso/agonistas , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/genética , Técnicas de Placa-Clamp , Receptores de GABA-A/química , Receptores de GABA-A/genética , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Reproducibilidad de los Resultados , Zinc/farmacología , Ácido gamma-Aminobutírico/metabolismoRESUMEN
Extracts of Feretia apodanthera Del. (Rubiaceae) have been extensively used in traditional Cameroonian medicine to treat a variety of diseases, including some neurological disorders. The present study was aimed to tests the anticonvulsant properties of the aqueous extract and the alkaloid fraction of the stem barks of Feretia apodanthera. The anticonvulsant investigation was carried out against bicuculline-, picrotoxin-, pentylenetetrazol-, Methyl-ß-carboline-3-carboxylate-, N-Methyl-D-aspartate-, 4-aminopyridine-, and maximal electroshock-induced seizures or turning behavior in mice. The aqueous extract protected mice against bicuculline-, picrotoxin-, pentylenetetrazol-, Methyl-ß-carboline-3-carboxylate-, N-methyl-D-aspartate -, 4-aminopyridine- and maximal electroshock-induced seizures or turning behavior. Also, N-Methyl-D-aspartate-, 4-aminopyridine- and maximal electroshock- induced seizures or turning behavior, were significantly antagonized by the alkaloid fraction (80mg/kg) from Feretia apodanthera. The total protection of mice provided by the aqueous extract against convulsions induced by pentylenetetrazol or picrotoxin was anagonized by flumazenil, a specific antagonist of the benzodiazepine site in the GABAA receptor complex. The aqueous extract of Feretia apodanthera (but not the alkaloid fraction) increased the brain GABA content and inhibited the GABA transaminase activity. In conclusion, Feretia apodanthera was revealed possessing anticonvulsant effects in mice, likely via the GABAergic neurotransmission.
Asunto(s)
Anticonvulsivantes/farmacología , Fitoterapia , Extractos Vegetales/farmacología , Rubiaceae , Convulsiones/tratamiento farmacológico , 4-Aminobutirato Transaminasa/metabolismo , Alcaloides/química , Animales , Anticonvulsivantes/química , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Moduladores del GABA/farmacología , Masculino , Ratones , Corteza de la Planta/química , Extractos Vegetales/química , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Agua/químicaRESUMEN
KEY POINTS: The role of the ß1 strand in GABAA receptor function is unclear. It lies anti-parallel to the ß2 strand, which is known to participate in receptor activation. Molecular dynamics simulation revealed solvent accessible residues within the ß1 strand of the GABAA ß3 homopentamer that might be amenable to analysis using the substituted Cys accessibility method. Cys substitutions from Asp43 to Thr47 in the GABAA α1 subunit showed that D43C and T47C reduced the apparent potency of GABA. F45C caused a biphasic GABA concentration-response relationship and increased spontaneous gating. Cys43 and Cys47 were accessible to 2-aminoethyl methanethiosulphonate (MTSEA) modification, whereas Cys45 was not. Both GABA and the allosteric agonist propofol reduced MTSEA modification of Cys43 and Cys47. By contrast, modification of Cys64 in the ß2 strand loop D was impeded by GABA but unaffected by propofol. These data reveal movement of ß1 strand loop G residues during agonist activation of the GABAA receptor. ABSTRACT: The GABAA receptor α subunit ß1 strand runs anti-parallel to the ß2 strand, which contains loop D, known to participate in receptor activation and agonist binding. However, a role for the ß1 strand has yet to be established. We used molecular dynamics simulation to quantify the solvent accessible surface area (SASA) of ß1 strand residues in the GABAA ß3 homopentamer structure. Residues in the complementary interface equivalent to those between Asp43 and Thr47 in the α1 subunit have an alternating pattern of high and low SASA consistent with a ß strand structure. We investigated the functional role of these ß1 strand residues in the α1 subunit by individually replacing them with Cys residues. D43C and T47C substitutions reduced the apparent potency of GABA at α1ß2γ2 receptors by 50-fold and eight-fold, respectively, whereas the F45C substitution caused a biphasic GABA concentration-response relationship and increased spontaneous gating. Receptors with D43C or T47C substitutions were sensitive to 2-aminoethyl methanethiosulphonate (MTSEA) modification. However, GABA-evoked currents mediated by α1(F45C)ß2γ2 receptors were unaffected by MTSEA, suggesting that this residue is inaccessible. Both GABA and the allosteric agonist propofol reduced MTSEA modification of α1(D43C)ß2γ2 and α1(T47C)ß2γ2 receptors, indicating movement of the ß1 strand even during allosteric activation. This is in contrast to α1(F64C)ß2γ2 receptors, where only GABA, but not propofol, reduced MTSEA modification. These findings provide the first functional evidence for movement of the ß1 strand during gating of the receptor and identify residues that are critical for maintaining GABAA receptor function.
Asunto(s)
Receptores de GABA-A/química , Receptores de GABA-A/fisiología , Metanosulfonato de Etilo/análogos & derivados , Metanosulfonato de Etilo/farmacología , Células HEK293 , Humanos , Simulación de Dinámica Molecular , Propofol/farmacología , Conformación Proteica en Lámina beta , Subunidades de Proteína/química , Subunidades de Proteína/fisiología , Ácido gamma-Aminobutírico/farmacologíaRESUMEN
Although the anticonvulsant activity of 3-hydroxy-3-ethyl-3-phenylproionamide (HEPP) is well-known, its use is limited by the pharmacotoxicological profile. We herein tested its fluorinated and chlorinated derivatives (F-HEPP and Cl-HEPP) with two seizure models, maximal electroshock seizures (MES), and intraperitoneal pentylenetetrazole (PTZ) administration. Neurotoxicity was examined via the rotarod test. With in silico methods, binding was probed on possible protein targets-GABAA receptors and the sodium channel Nav1.2. The median effective doses (ED50) of HEPP, F-HEPP, and Cl-HEPP in the MES seizure model were 129.6, 87.1, and 62.0 mg/kg, respectively, and 66.4, 43.5, and in the PTZ seizure model 43.5 mg/kg. The HEPP-induced neurotoxic effect, which occurred at twice the ED50 against MES (p < 0.05), did not occur with F-HEPP or Cl-HEPP. Docking studies revealed that all tested ligands bound to GABAA receptors on a site near to the benzodiazepine binding site. However, on the sodium channel open pore Nav1.2, R-HEPP had interactions similar to those reported for phenytoin, while its enantiomer and the ligands F-HEPP and Cl-HEPP reached a site that could disrupt the passage of sodium. Our results show that, as anticonvulsant agents, parahalogen substituted compounds have an advantageous pharmacotoxicological profile compared to their precursor.
Asunto(s)
Anticonvulsivantes , Hidrocarburos Clorados , Hidrocarburos Fluorados , Fenilpropionatos , Convulsiones/tratamiento farmacológico , Animales , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/química , Anticonvulsivantes/farmacología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Electrochoque , Hidrocarburos Clorados/efectos adversos , Hidrocarburos Clorados/farmacología , Hidrocarburos Fluorados/efectos adversos , Hidrocarburos Fluorados/química , Hidrocarburos Fluorados/farmacología , Masculino , Ratones , Simulación del Acoplamiento Molecular , Canal de Sodio Activado por Voltaje NAV1.2/metabolismo , Fenilpropionatos/efectos adversos , Fenilpropionatos/química , Fenilpropionatos/farmacología , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Convulsiones/metabolismoRESUMEN
Water hemlocks (Cicuta spp.) are acutely toxic members of the Umbellierae family; the toxicity is due to the presence of C17-polyacetylenes such as cicutoxin. There is only limited evidence of noncompetitive antagonism by C17-polyacetylenes at GABAA receptors. In this work with WSS-1 cells, we documented the noncompetitive blockade of GABAA receptors by an aqueous extract of water hemlock (Cicuta douglasii) and modulated the actions of the extract with a pretreatment of 10 µM midazolam.
Asunto(s)
Cicuta/química , Antagonistas de Receptores de GABA-A/toxicidad , Extractos Vegetales/toxicidad , Antagonistas de Receptores de GABA-A/química , Células HEK293 , Humanos , Extractos Vegetales/química , Receptores de GABA-A/químicaRESUMEN
In the present study, the orthosteric GABAA receptor (GABAAR) ligand 4,5,6,7-tetrahydroisothiazolo[5,4-c]pyridin-3-ol (Thio-THIP) was found to possess a highly interesting functional profile at recombinant human GABAARs and native rat GABAARs. Whereas Thio-THIP displayed weak antagonist activity at α1,2,5ß2,3γ2S and ρ1 GABAARs and partial agonism at α6ß2,3δ GABAARs expressed in Xenopus oocytes, the pronounced agonism exhibited by the compound at α4ß1δ and α4ß3δ GABAARs was contrasted by its negligible activity at the α4ß2δ subtype. To elucidate to which extent this in vitro profile translated into functionality at native GABAARs, we assessed the effects of 100 µm Thio-THIP at synaptic and extrasynaptic receptors in principal cells of four different brain regions by slice electrophysiology. In concordance with its α6ß2,3δ agonism, Thio-THIP evoked robust currents through extrasynaptic GABAARs in cerebellar granule cells. In contrast, the compound did not elicit significant currents in dentate gyrus granule cells or in striatal medium spiny neurons (MSNs), indicating predominant expression of extrasynaptic α4ß2δ receptors in these cells. Interestingly, Thio-THIP evoked differential degrees of currents in ventrobasal thalamus neurons, a diversity that could arise from differential expression of extrasynaptic α4ßδ subtypes in the cells. Finally, whereas 100 µm Thio-THIP did not affect the synaptic currents in ventrobasal thalamus neurons or striatal MSNs, it reduced the current amplitudes recorded from dentate gyrus granule cells, most likely by targeting perisynaptic α4ßδ receptors expressed at distal dendrites of these cells. Being the first published ligand capable of discriminating between ß2- and ß3-containing receptor subtypes, Thio-THIP could be a valuable tool in explorations of native α4ßδ GABAARs.
Asunto(s)
Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Agonistas de Receptores de GABA-A/farmacología , Isoxazoles/farmacología , Inhibición Neural/efectos de los fármacos , Inhibición Neural/fisiología , Receptores de GABA-A/metabolismo , Animales , Encéfalo/citología , Cerebelo/efectos de los fármacos , Cerebelo/fisiología , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/fisiología , Giro Dentado/efectos de los fármacos , Giro Dentado/fisiología , Relación Dosis-Respuesta a Droga , Humanos , Potenciales de la Membrana/efectos de los fármacos , Potenciales de la Membrana/fisiología , Neuronas/efectos de los fármacos , Neuronas/fisiología , Subunidades de Proteína/agonistas , Subunidades de Proteína/antagonistas & inhibidores , Subunidades de Proteína/metabolismo , Ratas , Receptores de GABA-A/química , Proteínas Recombinantes/efectos de los fármacos , Tálamo/efectos de los fármacos , Tálamo/fisiología , XenopusRESUMEN
Biphenylic compounds related to the natural products magnolol and 4'-O-methylhonokiol were synthesized, evaluated and optimized as positive allosteric modulators (PAMs) of GABA(A) receptors. The most efficacious compounds were the magnolol analog 5-ethyl-5'-hexylbiphenyl-2,2'-diol (45) and the honokiol analogs 4'-methoxy-5-propylbiphenyl-2-ol (61), 5-butyl-4'-methoxybiphenyl-2-ol (62) and 5-hexyl-4'-methoxybiphenyl-2-ol (64), which showed a most powerful potentiation of GABA-induced currents (up to 20-fold at a GABA concentration of 3µM). They were found not to interfere with the allosteric sites occupied by known allosteric modulators, such as benzodiazepines and N-arachidonoylglycerol. These new PAMs will be useful as pharmacological tools and may have therapeutic potential for mono-therapy, or in combination, for example, with GABA(A) receptor agonists.
Asunto(s)
Productos Biológicos/química , Compuestos de Bifenilo/química , Lignanos/química , Receptores de GABA-A/metabolismo , Regulación Alostérica , Animales , Productos Biológicos/metabolismo , Compuestos de Bifenilo/síntesis química , Compuestos de Bifenilo/metabolismo , Lignanos/síntesis química , Lignanos/metabolismo , Oocitos/metabolismo , Técnicas de Placa-Clamp , Unión Proteica , Isoformas de Proteínas/química , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Receptores de GABA-A/química , Receptores de GABA-A/genética , Relación Estructura-Actividad , Xenopus/crecimiento & desarrolloRESUMEN
Extrasynaptic δ-subunits containing GABAA receptors (δGABAARs) are sensitive targets for several commonly used hypnotic agents and mediate tonic neuronal inhibition. δGABAARs are highly expressed within the thalamus and their activation promotes a switch from tonic to burst firing in vitro. Here we test two hypotheses in vivo. (1) Activation of thalamic δGABAARs will elicit electrocortical signatures consistent with widespread thalamocortical burst firing such as increased delta oscillations (1-4 Hz) and reciprocal changes in spindle-like oscillations (7-14 Hz). (2) These signatures will be recapitulated by the general anesthetic etomidate, if the electrocortical effects of etomidate at the thalamus are mediated by δGABAARs. Microperfusion of the δGABAAR-preferring agonist 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP; 10 and 50 µM) into the ventrobasal complex produced significant effects on electrocortical activity in wild-type mice, but not in mice lacking δGABAARs (Gabrd(-/-)), i.e., the effects with THIP were dependent on δGABAARs. THIP (1) increased 1-4 Hz power in wakefulness and nonrapid-eye movement (NREM) sleep; (2) reduced spindle-like oscillations in NREM sleep; and (3) increased the speed of stable transitions into NREM sleep, indicating effects on state-space dynamics. In contrast, microperfusion of etomidate (10 and 30 µM) into the ventrobasal complex produced effects on electrocortical activity that were independent of δGABAARs, i.e., effects occurred in wild-type and Gabrd(-/-) mice. Etomidate (1) decreased 1-4 Hz power, increased 8-12 Hz, and/or 12-30 Hz power in all sleep-wake states; (2) increased spindle-like oscillations; and (3) increased REM sleep expression. These results indicate that thalamic δGABAARs promote electrocortical signatures of deep NREM sleep, but do not mediate the effects of etomidate at the thalamus in vivo.
Asunto(s)
Potenciales de Acción/fisiología , Relojes Biológicos/fisiología , Etomidato/farmacología , Red Nerviosa/fisiología , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Fases del Sueño/fisiología , Tálamo/fisiología , Potenciales de Acción/efectos de los fármacos , Animales , Relojes Biológicos/efectos de los fármacos , Hipnóticos y Sedantes/farmacología , Masculino , Ratones , Ratones Noqueados , Red Nerviosa/efectos de los fármacos , Subunidades de Proteína , Fases del Sueño/efectos de los fármacos , Tálamo/efectos de los fármacosRESUMEN
Terpinen-4-ol (4TRP) is a monoterpenoid alcoholic component of essential oils obtained from several aromatic plants. We investigated the psychopharmacological and electrophysiological activities of 4TRP in male Swiss mice and Wistar rats. 4TRP was administered intraperitoneally (i.p.) at doses of 25 to 200 mg/kg and intracerebroventricularly (i.c.v.) at concentrations of 10, 20, and 40 ng/2 µL. For in vitro experiments, 4TRP concentrations were 0.1 mM and 1.0 mM. 4TRP (i.p.) inhibited pentylenetetrazol- (PTZ-) induced seizures, indicating anticonvulsant effects. Electroencephalographic recordings showed that 4TRP (i.c.v.) protected against PTZ-induced seizures, corroborating the behavioural results. To determine whether 4TRP exerts anticonvulsant effects via regulation of GABAergic neurotransmission, we measured convulsions induced by 3-mercapto-propionic acid (3-MP). The obtained results showed involvement of the GABAergic system in the anticonvulsant action exerted by 4TRP, but flumazenil, a selective antagonist of the benzodiazepine site of the GABAA receptor, did not reverse the anticonvulsant effect, demonstrating that 4TRP does not bind to the benzodiazepine-binding site. Furthermore, 4TRP decreased the sodium current through voltage-dependent sodium channels, and thus its anticonvulsant effect may be related to changes in neuronal excitability because of modulation of these channels.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Convulsiones/tratamiento farmacológico , Terpenos/uso terapéutico , Animales , Anticonvulsivantes/química , Anticonvulsivantes/farmacología , Conducta Animal/efectos de los fármacos , Sitios de Unión , Fenómenos Electrofisiológicos/efectos de los fármacos , Flumazenil/farmacología , Antagonistas de Receptores de GABA-A/farmacología , Neuronas GABAérgicas/efectos de los fármacos , Neuronas GABAérgicas/metabolismo , Infusiones Intraventriculares , Inyecciones Intraperitoneales , Masculino , Ratones , Monoterpenos/química , Monoterpenos/farmacología , Monoterpenos/uso terapéutico , Pentilenotetrazol/toxicidad , Ratas , Ratas Wistar , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Convulsiones/inducido químicamente , Convulsiones/patología , Terpenos/química , Terpenos/farmacologíaRESUMEN
BACKGROUND: Valerian is commonly used for the treatment of insomnia and anxiety. Valerian extracts allosterically modulate GABA-A receptors and induced an anxiolytic activity. This activity is closely related to valerenic acid. In the present experiments it was investigated whether acetoxy valerenic acid may interfere with the anxiolytic action of valerenic acid. METHODS: Situational anxiety was measured using male CD-1 mice in the elevated plus maze test after oral administration of the test substances. In addition the body core temperature was measured. For the 3H-GABA binding assay dissected tissue from frontal cortex of male RjHan:WI rats were used. Statistical evaluation was performed by means of the non-parametric Kruskal-Wallies H-test, followed by the two-tailed Mann-Whitney U-test. RESULTS: Adding of acetoxy valerenic acid abolished the anxiolytic action of valerenic acid. There was no effect on body core temperature. Moreover, the valerian extract did not show any affinity to benzodiazepine binding sites. CONCLUSION: The determining compound for the observed anxiolytic effect of the valerian extract is its content of valerenic acid.
Asunto(s)
Ansiolíticos/farmacología , Ansiedad/tratamiento farmacológico , Indenos/farmacología , Extractos Vegetales/farmacología , Sesquiterpenos/farmacología , Valeriana/química , Animales , Ansiolíticos/química , Ansiolíticos/farmacocinética , Ansiedad/metabolismo , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Lóbulo Frontal/química , Lóbulo Frontal/metabolismo , Indenos/química , Indenos/farmacocinética , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Extractos Vegetales/química , Extractos Vegetales/farmacocinética , Ratas , Receptores de GABA-A/química , Receptores de GABA-A/efectos de los fármacos , Sesquiterpenos/química , Sesquiterpenos/farmacocinéticaRESUMEN
A dichloromethane extract of stems and roots of Pholidota chinensis (Orchidaceae) enhanced GABA-induced chloride currents (I(GABA)) by 132.75 ± 36.69% when tested at 100 µg/mL in a two-microelectrode voltage clamp assay, on Xenopus laevis oocytes expressing recombinant α1ß2γ2S GABA(A) receptors. By means of an HPLC-based activity profiling approach, the three structurally related stilbenoids coelonin (1), batatasin III (2), and pholidotol D (3) were identified in the active fractions of the extract. Dihydrostilbene 2 enhanced I(GABA) by 1512.19 ± 176.47% at 300 µM, with an EC50 of 52.51 ± 16.96 µM, while compounds 1 and 3 showed much lower activity. The relevance of conformational flexibility for receptor modulation by stilbenoids was confirmed with a series of 13 commercially available stilbenes and their corresponding semisynthetic dihydro derivatives. Dihydrostilbenes showed higher activity in the oocyte assay than their corresponding stilbenes. The dihydro derivatives of tetramethoxy-piceatannol (12) and pterostilbene (20) were the most active among these derivatives, but they showed lower efficiencies than compound 2. Batatasin III (2) showed high efficiency but no significant subunit specificity when tested on the receptor subtypes α1ß2γ2s, α2ß2γ2s, α3ß2γ2s, α4ß2γ2s, α5ß2γ2s, α1ß1γ2s, and α1ß3γ2s. Dihydrostilbenes represent a new scaffold for GABA(A) receptor modulators.
Asunto(s)
Orchidaceae/química , Receptores de GABA-A/química , Estilbenos/química , Animales , Oocitos/efectos de los fármacos , Oocitos/metabolismo , Orchidaceae/metabolismo , Técnicas de Placa-Clamp , Extractos Vegetales/química , Raíces de Plantas/química , Raíces de Plantas/metabolismo , Tallos de la Planta/química , Tallos de la Planta/metabolismo , Subunidades de Proteína/química , Subunidades de Proteína/genética , Subunidades de Proteína/metabolismo , Receptores de GABA-A/genética , Receptores de GABA-A/metabolismo , Estilbenos/aislamiento & purificación , Estilbenos/farmacología , Xenopus laevis/crecimiento & desarrolloRESUMEN
Insomnia is a prominent modern disease that affects an increasing population. Undesirable side effects of commercial drugs highlight the need to develop novel insomnia drugs. Virtual screening of traditional chinese medicine Database@Taiwan (TCM Database@Taiwan) identified 2-O-Caffeoyl tartaric acid (1), 2-O-Feruloyl tartaric acid (2), and Mumefural (3) as potential agonists for both gamma-amino butyric acid (GABA) or benzodiazepine (BZ) binding sites. The TCM candidates exhibited higher affinity than GABA and Zolpidem, a phenomenon that could be attributed to higher quantity of stabilizing H-bonds. Efficacy profiles using support vector machines and pharmacophore contour also suggest drug potential of the TCM candidates. Fragments added to the de novo derivatives 3a, 3b, 3c for GABA binding site, and 1a, 2a, and 3d for BZ binding site contributed to new binding sites and structural stability, further optimizing binding to GABA or BZ binding sites. Increased opening of the ion channel by candidate ligands provide strong support for their potential biological functions. The dual binding properties of the TCM candidates present a unique opportunity to develop twin-targeting drugs with less side effects. Derivative structures can be used as starting points for developing high affinity GABAA receptor agonists with specificity towards GABA binding site and BZ binding site.
Asunto(s)
Ácidos Cafeicos/química , Ácido Cítrico/análogos & derivados , Ácidos Cumáricos/química , Medicamentos Herbarios Chinos/química , Furanos/química , Agonistas del GABA/química , Receptores de GABA-A/química , Trastornos del Inicio y del Mantenimiento del Sueño/terapia , Tartratos/química , Sitios de Unión , Ácido Cítrico/química , Bases de Datos de Compuestos Químicos , Humanos , Medicina Tradicional China , Simulación de Dinámica Molecular , Ácido gamma-Aminobutírico/químicaRESUMEN
Gamma amino butyric acid receptors (GABA) are major therapeutic targets for the development of drugs in neurological and psychiatric disorders. The new generation of GABAA modulators is targeting subtype selectivity and low/partial efficacy on the receptor to potentially overcome the adverse effects described for drugs with full agonist profile. We evaluated a screening approach to measure the relative efficacy of GABAA positive allosteric modulators (PAM) using automated patch clamp and fluorescence membrane potential assays. We determined that the use of an internal comparator (zolpidem), tested on each cell in parallel to the test compound, provides a reliable approach to measure and compare the relative efficacy of PAM ligands. Patch clamp recordings on recombinant GABAA receptors, using a multiple drug addition protocol, allows us to rank PAM ligands with different levels of efficacies. We observed that fluorescence membrane potential assays are not predictive of the relative efficacies of GABAA PAM ligands.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Agonistas de Receptores de GABA-A/farmacología , Antagonistas de Receptores de GABA-A/farmacología , Receptores de GABA-A/metabolismo , Regulación Alostérica/efectos de los fármacos , Animales , Células CHO , Línea Celular , Cricetulus , Descubrimiento de Drogas , Humanos , Técnicas de Placa-Clamp , Receptores de GABA-A/químicaRESUMEN
Taurine is a semi-essential sulfonic acid found at high concentrations in plasma and mammalian tissues which regulates osmolarity, ion channel activity and glucose homeostasis. The structural requirements of GABAA-receptors (GABAAR) gated by taurine are not yet known. We determined taurine potency and efficacy relative to GABA at different types of recombinant GABAAR occurring in central histaminergic neurons of the mouse hypothalamic tuberomamillary nucleus (TMN) which controls arousal. At binary α(1/2)ß(1/3) receptors taurine was as efficient as GABA, whereas incorporation of the γ(1/2) subunit reduced taurine efficacy to 60-90% of GABA. The mutation γ(2F77I), which abolishes zolpidem potentiation, significantly reduced taurine efficacy at recombinant and native receptors compared to the wild type controls. As taurine was a full- or super- agonist at recombinant αxß1δ-GABAAR, we generated a chimeric γ(2) subunit carrying the δ subunit motif around F77 (MTVFLH). At α(1/2)ß(1)γ2(MTVFLH) receptors taurine became a super-agonist, similar to δ-containing ternary receptors, but remained a partial agonist at ß3-containing receptors. In conclusion, using site-directed mutagenesis we found structural determinants of taurine's partial agonism at γ-containing GABAA receptors. Our study sheds new light on the ß1 subunit conferring the widest range of taurine-efficacies modifying GABAAR function under (patho)physiological conditions.
Asunto(s)
Agonistas de Receptores de GABA-A/farmacología , Receptores de GABA-A/genética , Receptores de GABA-A/metabolismo , Taurina/farmacología , Secuencia de Aminoácidos , Animales , Agonistas de Receptores de GABA-A/metabolismo , Hipotálamo/citología , Masculino , Ratones , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Mutación , Neuronas/citología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Subunidades de Proteína/química , Subunidades de Proteína/metabolismo , Piridinas/farmacología , Receptores de GABA-A/química , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Alineación de Secuencia , Taurina/metabolismo , Xenopus , Zolpidem , Ácido gamma-Aminobutírico/metabolismoRESUMEN
Ionotropic GABA(A) receptors (GABA(A)Rs), which mediate inhibitory neurotransmission in the central nervous system, are implicated in the behavioral effects of alcohol and alcoholism. Site-directed mutagenesis studies support the presence of discrete molecular sites involved in alcohol enhancement and, more recently, inhibition of GABA(A)Rs. We used Xenopus laevis oocytes to investigate the 6' position in the second transmembrane region of GABA(A)Rs as a site influencing alcohol inhibition. We asked whether modification of the 6' position by substitution with larger residues or methanethiol labeling [using methyl methanethiosulfonate (MMTS)] of a substituted cysteine, reduced GABA action and/or blocked further inhibition by alcohols. Labeling of the 6' position in either α2 or ß2 subunits reduced responses to GABA. In addition, methanol and ethanol potentiation increased after MMTS labeling or substitution with tryptophan or methionine, consistent with elimination of an inhibitory site for these alcohols. Specific alcohols, but not the anesthetic etomidate, competed with MMTS labeling at the 6' position. We verified a role for the 6' position in previously tested α2ß2 as well as more physiologically relevant α2ß2γ2s GABA(A)Rs. Finally, we built a novel molecular model based on the invertebrate glutamate-gated chloride channel receptor, a GABA(A)R homolog, revealing that the 6' position residue faces the channel pore, and modification of this residue alters volume and polarity of the pore-facing cavity in this region. These results indicate that the 6' positions in both α2 and ß2 GABA(A)R subunits mediate inhibition by short-chain alcohols, which is consistent with the presence of multiple counteracting sites of action for alcohols on ligand-gated ion channels.